18-Jun-2014 - Big pharma is moving towards strategic partnerships with CMOs, according to speakers at the Global Pharmaceutical Contract Manufacturing (GPCM) Conference, with the ideal number of partners being ten.
11-Jun-2014 - When it comes to pharma acquisitions size does matter, according to analyst Ross Muken who says the momentary lapse in megamergers means business as usual for CROs.
29-May-2014 - Hikma Pharmaceuticals says it is evaluating Ben Venue’s manufacturing facility as an option in its $300m (€220m) acquisition of Bedford Laboratories.
27-May-2014 - Eli Lilly is maintaining greater in-house control as manufacturing processes become more complex, whilst MSD is leveraging external over-capacity to fulfil its needs, the firms told Outsourcing-Pharma.com during a recent...
07-May-2014 - Huntingdon Life Sciences has acquired contract research and animal models firm Harlan Laboratories, making it the third largest preclinical research organisation, according to the company.
06-May-2014 - Quintiles and Covance have re-iterated previous CROs’ upbeat stances on the prospect for further pharma M&A as they both reported revenue growth for the quarter.
05-May-2014 - A mega-merger between Pfizer and AstraZeneca would bring increased business to CROs say Icon and Parexel, if past experiences are to go by.
28-Apr-2014 - The relationship between private equity (PE) management and that of its CRO is “pivotal,” according to the Chairman of one pharma group, as PE’s undefined objectives and exit strategies are...
24-Apr-2014 - Biogen Idec’s five-year deal is the latest example of biopharma embracing the strategic partnership model, but the choice of Quintiles is somewhat of a surprise, according to ISI analyst Ross...
10-Apr-2014 - Much of the $91bn (€66bn) raised in biotech capital over the last twelve months will end up in the hands of the CRO industry, according to a survey from analyst...
03-Apr-2014 - Pernix Therapeutics will no longer be a CMO as it has signed a definitive agreement to divest its Houston, Texas-based manufacturing operations to Woodfield Pharmaceutical to cut costs.
02-Apr-2014 - Argenta and BioFocus will add approximately $70m (€51m) to Charles River Laboratories’ 2014 revenues, the firm and an analyst say.
26-Mar-2014 - Aenova says the acquisition of Haupt Pharma and Patheon’s merger with DSM are evidence of consolidation in the CMO industry, as it looks to further increase its global footprint.
24-Mar-2014 - Evotec AG has bought an asset management company that specialises in bringing academic discovery and development innovations to the attention of pharma and biopharma sponsors.
20-Mar-2014 - Patheon and DSM’s Pharma Products merger is “highly complementary” with crossover limited to North American oral solid manufacturing growth, says DPx as it targets further growth opportunities.
14-Mar-2014 - Patheon brings fill/finish capabilities to DSM’s biomanufacturing services, President of Biopharma at the recently merged company DPx told Biopharma-Reporter.com in an exclusive interview.
13-Mar-2014 - In an exclusive interview, Patheon Executive Mike Lehmann talks DSM integration, further growth and how consolidation amongst CMOs may be driving strategic alliances with pharma.
13-Mar-2014 - Preclinical CRO Charles River Labs has announced plans to buy discovery services firms Argenta and BioFocus from Galapagos NV.
10-Mar-2014 - In a sign of further consolidation, CRO INC Research has acquired CRO MEK Consulting and will absorb its more than 40 employees based in the Middle East and north Africa.
26-Feb-2014 - DSM has reported modest growth in its pharma business as a shareholders advisory firm comes out in favour of the upcoming merger with Patheon.
24-Feb-2014 - CRO consolidation has left market opportunities for providers who serve mid-size pharma, UK-based private equity firm Cinven says as it acquires Medpace.
24-Feb-2014 - Icon says it intends to continue its M&A strategy focusing on capabilities, geographies and technologies as it reports a robust 2013.
19-Feb-2014 - Mid-tier pharma mergers and a shift to more complex trials will benefit broad-based CROs, whilst smaller outsourcing partners will be forced to consolidate, an industry report by Citi Research predicts.
12-Feb-2014 - Charles River Laboratories says it will shutter a Research Models and Services (RMS) facility in Michigan as softened demand for the sector offset a strong year for its preclinical service...
03-Feb-2014 - CROs CTI Trial and Clinical Consulting recently acquired Community Research, David Blume, managing director of Edgemont Capital, told us.